The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Neurosurgical review
- Publicado em
- 26 abr 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma
Mohammad Amin Habibi, Farhang Rashidi, Bardia Hajikarimloo, Shaghayegh Karami, Sahar Fathi Tavani, Amirhossein Zare, Mohammad Sina Mirjani, Ali Allahdadi, Kimia Didehvar, Ibrahim Mohammadzadeh et al.
Descritores MeSH
- Protein Kinase Inhibitors
- Brain Neoplasms
- Glioblastoma
- Glioma
- Receptors, Vascular Endothelial Growth Factor
- Progression-Free Survival
- Humans
- Tyrosine Kinase Inhibitors
- Adult
- Middle Aged
Veja também
Estudos relacionados
- The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma
- Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis
- The clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma
- Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis